SHP1 Antibody

What is SHP1 and why is it important in immunological research?

SHP1, also known as protein tyrosine phosphatase non-receptor type 6 (PTPN6), is a 595-amino acid protein belonging to the Protein-tyrosine phosphatase family, Non-receptor class 2 subfamily . It functions as a key regulator of cell survival, proliferation, differentiation, and migration in hematopoietic cells . SHP1's importance in immunological research stems from its role as a central effector for inhibitory immunoreceptors containing Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs) and Immunoreceptor Tyrosine-based Switch Motifs (ITSMs) . The protein is primarily localized in both cytoplasmic and nuclear compartments, where it mediates critical signaling events . Understanding SHP1 function is essential for elucidating immune checkpoint mechanisms, as it works alongside SHP2 to regulate T cell activation and inhibitory pathways. These phosphatases have distinct binding preferences and regulatory roles that collectively shape immune responses and represent potential therapeutic targets for modulating immune system function .

How do SHP1 and SHP2 differ functionally in immune signaling pathways?

SHP1 and SHP2 exhibit distinct recruitment patterns to immune checkpoint receptors despite their structural similarities. Research has demonstrated that certain receptors like PD-1 (Programmed Cell Death Protein 1) preferentially recruit SHP2 but not SHP1, while others such as BTLA (B and T Lymphocyte Attenuator) recruit both phosphatases with a preference for SHP1 . These differential recruitment patterns significantly impact downstream signaling cascades and ultimately influence T cell activation outcomes. The molecular basis for this specificity dichotomy has been traced to structural differences between the SH2 domains of SHP1 and SHP2, as well as sequence variations in the ITIMs of different receptors . For instance, cell-based assays have consistently shown that PD-1 becomes tyrosine phosphorylated and recruits SHP2 in a time-dependent manner but fails to recruit SHP1, whereas BTLA clearly recruits both phosphatases with stronger affinity for SHP1 . These functional differences are critical considerations when designing experiments to study immune checkpoint regulation and when interpreting antibody-based detection of these phosphatases in different signaling contexts.

What are the key applications of SHP1 antibodies in immunological research?

SHP1 antibodies serve multiple critical functions in immunological research across various experimental platforms. They are extensively used in Western blotting (WB) to detect and quantify SHP1 protein levels in cell lysates and immunoprecipitates, providing insights into protein expression and modifications under different conditions . Immunoprecipitation (IP) with SHP1 antibodies enables researchers to isolate SHP1 protein complexes for subsequent analysis of binding partners and post-translational modifications . Immunohistochemistry applications, particularly with paraffin-embedded tissues (IHC-p), allow visualization of SHP1 distribution in tissue specimens, offering spatial information about protein localization in physiological and pathological contexts . For cellular imaging studies, SHP1 antibodies are instrumental in immunofluorescence experiments to observe the recruitment of SHP1 to signaling complexes like PD-1 microclusters using techniques such as total internal reflection fluorescence microscopy (TIRF-M) . Additionally, functional assays employing SHP1 antibodies help elucidate the role of this phosphatase in inhibitory receptor signaling by measuring downstream effects on cytokine production, such as IL-2 secretion in T cells following receptor engagement .

What factors should I consider when selecting an appropriate SHP1 antibody?

When selecting an SHP1 antibody for research, several critical factors must be carefully evaluated to ensure optimal experimental outcomes. First, consider the specific application requirements—different experimental techniques (Western blotting, immunoprecipitation, immunohistochemistry, or flow cytometry) may require antibodies with distinct properties and validation profiles . The species reactivity is paramount; while many antibodies target human SHP1, cross-reactivity with mouse or other species should be confirmed if working with animal models . Clonality is another important consideration—monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies may provide stronger signals by recognizing multiple epitopes but potentially with increased background . The specific epitope recognized by the antibody is crucial, particularly when studying phosphorylated forms or specific domains of SHP1; some antibodies target the phosphorylated Tyr564 residue, while others recognize different regions of the protein . Additionally, evaluate the validation data provided by suppliers, including positive and negative controls, to ensure the antibody's specificity and sensitivity in your experimental system . Finally, consider conjugation options (unconjugated or fluorophore/enzyme-labeled) based on your detection methods and experiment design requirements .

What controls should be included when using SHP1 antibodies in experiments?

Implementing appropriate controls when using SHP1 antibodies is essential for generating reliable and interpretable research data. Positive controls should include cell lines or tissues known to express high levels of SHP1, such as hematopoietic cell lines, which help confirm antibody functionality and establish expected signal patterns . Conversely, negative controls might involve cells with SHP1 knocked out using CRISPR-Cas9 technology, as demonstrated in studies examining SHP1 recruitment to immune receptors . Isotype controls matching the SHP1 antibody class (IgG1, IgG2a, etc.) but lacking specificity for the target should be included to assess non-specific binding, particularly in flow cytometry and immunohistochemistry applications. For phospho-specific SHP1 antibodies, controls should include samples treated with phosphatase inhibitors to preserve phosphorylation and samples treated with phosphatases to remove phosphorylation . When studying SHP1 recruitment to receptors like PD-1, domain-swapping mutants (replacing SHP1 domains with corresponding SHP2 domains) provide excellent controls to elucidate binding specificity mechanisms . Additionally, peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, can validate binding specificity by demonstrating signal reduction when the antibody's binding site is blocked.

How can I study SHP1 recruitment to immune checkpoint receptors in intact cells?

Studying SHP1 recruitment to immune checkpoint receptors in intact cells requires sophisticated experimental approaches that preserve physiological signaling dynamics. Total Internal Reflection Fluorescence Microscopy (TIRF-M) represents a powerful technique for visualizing SHP1 recruitment to receptor microclusters at the cell membrane with exceptional signal-to-noise ratio . This approach can be implemented by generating T cells expressing fluorescently tagged receptors (such as PD-1-mGFP) and stimulating them on supported lipid bilayers (SLBs) containing ligands like PD-L1, along with other stimulatory molecules such as anti-CD3ε antibodies . To detect endogenous SHP1, researchers can fix cells following stimulation, permeabilize them with saponin (0.1%), and stain with anti-SHP1 antibodies followed by fluorophore-conjugated secondary antibodies . Alternatively, cells can be engineered to express fluorescently tagged SHP1 (e.g., mCherry-SHP1) to enable real-time imaging of recruitment dynamics . For biochemical verification, antigen-presenting cell (APC) – T cell coculture assays can be employed, wherein receptor-expressing T cells are stimulated with ligand-expressing APCs (such as Raji B cells), followed by immunoprecipitation of the receptor and immunoblotting for co-precipitated SHP1 . Quantification of recruitment can be achieved by calculating the ratio of SHP1 fluorescence intensity to receptor fluorescence intensity within microclusters using image analysis software like Fiji .

What molecular features determine differential SHP1 versus SHP2 recruitment to immune receptors?

The molecular determinants governing differential recruitment of SHP1 versus SHP2 to immune receptors involve complex structural interactions between phosphatase SH2 domains and receptor phosphotyrosine motifs. Research has identified that the C-terminal SH2 domain (cSH2) plays a critical role in this discrimination process—swapping the cSH2 domain of SHP1 with that of SHP2 markedly enhances SHP1 recruitment to PD-1 microclusters, while swapping the N-terminal SH2 domain (nSH2) has only minor effects . Furthermore, a single residue at the +1 position relative to the phosphotyrosine (pY+1) in the ITIM sequence serves as a critical gatekeeper for SHP1 binding . Specifically, the presence of a medium-sized nonpolar residue (alanine, valine, leucine, or isoleucine) at this position strongly promotes SHP1 recruitment, whereas glycine (as in PD-1's ITIM) or bulky/polar residues prevent efficient binding . This specificity arises from a hydrophobic pocket in SHP1's nSH2 domain that coordinates the side chain of the pY+1 residue, with optimal binding occurring with residues of intermediate size . Systematic mutation studies have revealed a bell-shaped dependence of SHP1 recruitment on the molecular volume of nonpolar residues at the pY+1 position, peaking with leucine and isoleucine . These molecular insights explain why BTLA, with alanine at the pY+1 position in its ITIM (IVYASL), efficiently recruits SHP1, while PD-1, with glycine at this position (VDYGEL), does not .

How do mutations in the ITIM domain affect SHP1 recruitment and functional outcomes?

Mutations in the Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM) domain significantly impact SHP1 recruitment and consequently alter functional inhibitory outcomes. Research has demonstrated that substituting the glycine residue at the pY+1 position of PD-1's ITIM with alanine (G224A) substantially enhances SHP1 recruitment to PD-1 microclusters . This single residue substitution transforms PD-1 from a predominantly SHP2-recruiting receptor to one capable of efficiently recruiting SHP1 . Similarly, replacing the entire PD-1 ITIM sequence with BTLA's ITIM or with ITIMs from other inhibitory receptors like Siglec6, Siglec9, CD300LF, and SIRPα—all containing alanine at the pY+1 position—significantly increases SHP1 recruitment . The functional consequences of these mutations are substantial, as demonstrated by IL-2 secretion assays. T cells expressing PD-1 variants with enhanced SHP1 recruitment (G224A, G224V, G224L, or G224I) exhibit significantly stronger inhibition of IL-2 secretion compared to cells expressing wild-type PD-1 . This functional enhancement is specific to mutations introducing medium-sized nonpolar residues, as bulkier residues like phenylalanine or tryptophan fail to enhance inhibitory function . These findings establish a direct link between molecular determinants of SHP1 recruitment and functional inhibitory outcomes in immune checkpoint receptor signaling, highlighting the critical role of ITIM sequence composition in determining receptor function .

What experimental approaches can distinguish between SHP1 and SHP2 binding specificity?

Distinguishing between SHP1 and SHP2 binding specificity requires a multi-faceted experimental approach that combines biophysical, biochemical, and cellular imaging techniques. Surface Plasmon Resonance (SPR) provides quantitative measurements of binding affinities between phosphotyrosine motifs and individual SH2 domains, enabling precise comparison of all potential pY:SH2 interactions involved in receptor recruitment of SHP1 and SHP2 . Domain-swapping experiments, where the SH2 domains of SHP1 are replaced with those of SHP2 (and vice versa), help identify which domains contribute most significantly to binding specificity . These chimeric phosphatases can be expressed in cells as fluorescently tagged proteins to visualize their recruitment to receptor microclusters using Total Internal Reflection Fluorescence Microscopy (TIRF-M) . For biochemical verification, immunoprecipitation followed by immunoblotting can assess recruitment of endogenous or tagged phosphatases to receptors under various stimulation conditions . Site-directed mutagenesis of specific residues within receptor ITIMs allows systematic evaluation of how individual amino acids contribute to phosphatase selectivity . Functional assays measuring downstream effects, such as IL-2 secretion or T cell proliferation, can then correlate phosphatase recruitment patterns with biological outcomes . Combining these approaches provides a comprehensive understanding of the molecular basis for differential SHP1 versus SHP2 recruitment to immune receptors.

How can I quantitatively measure SHP1 binding affinity to different phosphotyrosine motifs?

Quantitatively measuring SHP1 binding affinity to different phosphotyrosine motifs requires precise biophysical and biochemical techniques that can detect and characterize protein-protein interactions. Surface Plasmon Resonance (SPR) represents a gold standard approach, allowing real-time measurement of binding kinetics and affinity constants (KD) between purified SHP1 SH2 domains and synthetic phosphopeptides representing different ITIM or ITSM sequences . When designing such experiments, both individual SH2 domains (nSH2 and cSH2) and tandem SH2 constructs should be tested to account for potential cooperative binding effects. Isothermal Titration Calorimetry (ITC) offers an alternative solution-based method that provides both binding affinity and thermodynamic parameters (ΔH, ΔS) of the interaction, offering insights into the energetic basis of binding specificity. For cellular contexts, microscale thermophoresis (MST) or fluorescence polarization assays using fluorescently labeled phosphopeptides can measure interactions in more complex environments. Quantification of SHP1 recruitment to receptor microclusters in intact cells provides complementary data that integrates various regulatory mechanisms operating in physiological settings; this can be achieved by normalizing SHP1 fluorescence intensity to receptor fluorescence intensity within defined microcluster regions using image analysis software like Fiji . The collective data from these approaches allows researchers to establish a comprehensive binding affinity profile that explains differential recruitment patterns observed in cellular studies.

What experimental systems are optimal for studying SHP1 function in immune cells?

Several experimental systems have proven effective for investigating SHP1 function in immune cells, each offering distinct advantages depending on the research question. Jurkat T cell lines provide a well-established system for studying SHP1 in T cell signaling, particularly when engineered to express fluorescently tagged proteins (like PD-1-mGFP) and stimulated with ligand-expressing antigen-presenting cells or supported lipid bilayers . These cells can be further modified using CRISPR-Cas9 technology to generate SHP1 or SHP2 knockout lines, enabling clean assessment of phosphatase-specific effects . Primary human or mouse T cells offer a more physiologically relevant context, though they present additional technical challenges for manipulation and imaging. For biochemical analyses, coculture systems involving receptor-expressing T cells (e.g., PD-1-mGFP-transduced Jurkat cells) and ligand-expressing B cells (e.g., PD-L1-transduced Raji cells) provide a controlled setting for studying receptor phosphorylation and SHP1/SHP2 recruitment . Supported lipid bilayers (SLBs) containing purified receptor ligands and stimulatory molecules represent an elegant system for high-resolution imaging of SHP1 recruitment to receptor microclusters using TIRF microscopy . This approach enables precise quantification of recruitment dynamics in a controlled environment that mimics the immunological synapse. For functional studies, cytokine release assays (e.g., IL-2 ELISA) with cells expressing wild-type or mutant receptors provide direct readouts of how SHP1 recruitment impacts T cell activation .

What are the best fixation and permeabilization methods for SHP1 immunofluorescence staining?

Optimal fixation and permeabilization methods for SHP1 immunofluorescence staining must preserve both protein localization and epitope accessibility while maintaining cellular architecture. For cells stimulated on supported lipid bilayers (SLBs), a gentle fixation protocol using 2% paraformaldehyde (PFA) at room temperature for 15 minutes effectively preserves the structure of membrane microclusters while stabilizing protein-protein interactions . This approach maintains the native distribution of SHP1 and its association with receptors like PD-1. Following fixation, a balanced permeabilization approach using 0.1% saponin in PBS containing 3% BSA for 30 minutes at room temperature provides sufficient access to intracellular epitopes while minimizing disruption of membrane structures . This method is particularly suitable for detecting SHP1 recruitment to membrane-proximal signaling complexes. For detection of nuclear SHP1, which represents another significant pool of this phosphatase, more robust permeabilization with 0.1-0.3% Triton X-100 may be necessary to ensure antibody access to nuclear compartments. When studying phosphorylated forms of SHP1, the addition of phosphatase inhibitors to all buffers is critical to prevent epitope loss during processing. After permeabilization, overnight incubation with primary anti-SHP1 antibodies at 4°C followed by appropriate fluorophore-conjugated secondary antibodies (1 hour at room temperature) typically yields optimal staining results .

How can I optimize Western blotting protocols for detecting SHP1 in complex samples?

Optimizing Western blotting protocols for SHP1 detection in complex samples requires attention to several critical parameters that influence sensitivity and specificity. Sample preparation should include appropriate lysis buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride) and protease inhibitors to preserve SHP1 integrity and phosphorylation status, particularly when studying phospho-specific forms . For immune cell lysates, RIPA buffer supplemented with 1% NP-40 effectively solubilizes membrane-associated SHP1 while maintaining protein stability. When separating proteins by SDS-PAGE, 8-10% polyacrylamide gels provide optimal resolution for SHP1 (approximately 68 kDa), with extended running times improving separation from similarly sized proteins. During transfer to membranes, PVDF membranes generally offer superior protein retention compared to nitrocellulose for SHP1 detection, with semi-dry transfer systems providing efficient results for this molecular weight range. Blocking with 5% non-fat dry milk in TBST is typically sufficient, though 3-5% BSA may provide lower background when using phospho-specific antibodies. Primary antibody incubation should be optimized for each specific antibody, but overnight incubation at 4°C at dilutions between 1:1000 and 1:5000 often yields the best signal-to-noise ratio for SHP1 antibodies . For detection, enhanced chemiluminescence (ECL) systems with exposure times tailored to signal strength provide reliable results, while fluorescently-labeled secondary antibodies offer advantages for quantitative analysis and multiplexing with other proteins of interest.

What are the key considerations for immunoprecipitation experiments targeting SHP1?

Successful immunoprecipitation (IP) experiments targeting SHP1 require careful consideration of multiple technical factors that influence specificity and yield. Selection of an appropriate antibody is paramount—antibodies validated specifically for IP applications should be prioritized, as not all Western blot-validated antibodies perform well in IP contexts . Cell lysis conditions must balance efficient protein extraction with preservation of protein-protein interactions; for studies of SHP1 interactions with immune receptors, gentler lysis buffers containing 1% digitonin or CHAPS often better preserve complexes compared to more stringent RIPA buffers . Pre-clearing lysates with appropriate control beads (Protein A/G) reduces non-specific binding, while reserving a portion of the input lysate is essential for normalization and validation. The antibody-to-lysate ratio requires optimization, typically starting with 2-5 μg antibody per 500 μg total protein and adjusting based on results. For kinetic studies examining time-dependent recruitment of SHP1 to receptors like BTLA, precise timing of stimulation before lysis is critical—the protocol described in the literature involves stimulating cells for specific time intervals (e.g., 5, 10, 20 minutes) before lysis and immunoprecipitation . When studying phosphorylation-dependent interactions, all buffers should contain phosphatase inhibitors to prevent dephosphorylation during processing. Washing conditions represent another critical variable—stringent washes reduce background but may disrupt weaker interactions, necessitating optimization based on the specific interaction being studied. Finally, elution can be performed using either reducing sample buffer for maximum recovery or gentler methods like peptide competition when maintaining complex integrity is important.

What imaging techniques are most effective for visualizing SHP1 localization and dynamics?

Several advanced imaging techniques offer distinct advantages for visualizing SHP1 localization and dynamics in various research contexts. Total Internal Reflection Fluorescence Microscopy (TIRF-M) represents a particularly powerful approach for studying SHP1 recruitment to membrane-proximal signaling complexes, as it selectively illuminates a thin section (~100-200 nm) at the cell-substrate interface . This technique provides exceptional signal-to-noise ratio for visualizing events at the plasma membrane, such as SHP1 recruitment to PD-1 or BTLA microclusters following receptor engagement . For three-dimensional visualization of SHP1 distribution throughout the cell, including its nuclear localization, confocal microscopy with optical sectioning capabilities is more appropriate. When studying dynamic recruitment processes, spinning disk confocal microscopy offers improved temporal resolution compared to conventional confocal systems. For live-cell imaging of SHP1 dynamics, fluorescent protein tags (mCherry, GFP) can be fused to SHP1, enabling real-time observation of recruitment kinetics and protein movement . Super-resolution techniques like Structured Illumination Microscopy (SIM) or Stochastic Optical Reconstruction Microscopy (STORM) provide enhanced spatial resolution beyond the diffraction limit, revealing the nanoscale organization of SHP1 within signaling complexes. For studying interaction dynamics, Förster Resonance Energy Transfer (FRET) between appropriately tagged SHP1 and binding partners offers insights into protein proximity and interaction kinetics in living cells.

What are common issues with SHP1 antibody staining and how can they be resolved?

Researchers frequently encounter several challenging issues when performing SHP1 antibody staining that require systematic troubleshooting approaches. High background signal often results from insufficient blocking or excessive antibody concentration; this can be addressed by extending blocking time with 3-5% BSA or serum matching the secondary antibody host species, and by titrating primary antibodies to determine optimal concentrations . Weak or absent specific signal may stem from epitope masking during fixation; testing alternative fixation methods (methanol vs. paraformaldehyde) or implementing heat-mediated antigen retrieval can improve epitope accessibility . Non-specific nuclear staining is particularly problematic when studying SHP1, which has both cytoplasmic and nuclear localization; validating specificity through appropriate knockout controls and using monoclonal antibodies targeting specific domains can help distinguish true from false signals . Cross-reactivity with SHP2 represents another significant concern due to structural similarities between these phosphatases; confirming antibody specificity using cells deficient in either SHP1 or SHP2 is essential for accurate interpretation . Inconsistent staining patterns between experiments often stem from variations in cell stimulation, fixation timing, or permeabilization conditions; standardizing these parameters and including positive control samples in each experiment helps establish reliable protocols . For phospho-specific SHP1 antibodies, rapid dephosphorylation during sample processing may lead to signal loss; incorporating phosphatase inhibitors in all buffers and minimizing processing time between stimulation and fixation can preserve phospho-epitopes .

How do I quantify SHP1 recruitment to cellular signaling complexes?

Quantifying SHP1 recruitment to cellular signaling complexes requires robust analytical approaches that account for both signal specificity and relative recruitment levels. For microscopy-based quantification, the ratio of SHP1 fluorescence intensity to receptor fluorescence intensity within defined microcluster regions provides a normalized measure of recruitment that controls for variations in receptor expression and clustering . This approach can be implemented using image analysis software like Fiji (ImageJ), following a standardized workflow: first, generate mask images identifying receptor microcluster areas by applying background subtraction to receptor channel images; second, measure fluorescence intensities of both SHP1 and receptor signals within these masked regions; third, calculate the SHP1/receptor fluorescence intensity ratio for each cell or region of interest . For biochemical quantification following immunoprecipitation, densitometric analysis of immunoblot bands for co-precipitated SHP1 normalized to the immunoprecipitated receptor provides a measure of relative recruitment . When comparing recruitment across different receptor variants or conditions, statistical analysis should incorporate appropriate tests (t-tests or ANOVA with post-hoc comparisons) to determine significance of observed differences . For kinetic studies, plotting normalized recruitment values against time or stimulation conditions reveals temporal dynamics and relative recruitment efficiency . To ensure reliability, all quantification should include multiple biological replicates (n≥3) and technical replicates, with clear reporting of sample sizes, statistical methods, and variability measures.

What explains discrepancies in SHP1 detection between different experimental approaches?

Discrepancies in SHP1 detection between different experimental approaches often stem from multiple technical and biological factors that influence detection sensitivity and specificity. Antibody epitope accessibility varies significantly between techniques—denatured epitopes in Western blotting may be readily detected while native conformations in immunofluorescence might mask the same epitope, leading to divergent results with the same antibody . Differences in SHP1 phosphorylation states can dramatically affect antibody recognition, particularly for phospho-specific antibodies or when phosphorylation alters protein conformation; this is especially relevant when comparing results from stimulated versus unstimulated conditions . The dynamic nature of SHP1 recruitment to signaling complexes means that temporal factors become critical—slight variations in stimulation timing or sample processing can lead to substantially different results when studying transient interactions . Subcellular compartmentalization of SHP1 pools (cytoplasmic versus nuclear) may be differentially preserved or detected depending on experimental approach, with some techniques better capturing one pool over another . Sample preparation methods significantly impact protein complexes—harsh lysis conditions used for Western blotting may disrupt weaker interactions that remain intact in gentler fixation protocols used for imaging . Cross-reactivity with SHP2 represents another source of discrepancy, particularly with antibodies targeting conserved regions; this can lead to false positive signals in techniques with limited resolving power . Resolution limitations of different techniques also contribute to discrepancies—diffraction-limited conventional microscopy may fail to distinguish closely associated proteins that can be separated by super-resolution approaches or biochemical techniques .

How can I confirm the specificity of observed SHP1 recruitment in my experiments?

Confirming the specificity of observed SHP1 recruitment requires implementing multiple complementary controls and validation approaches. Genetic approaches represent the gold standard—utilizing CRISPR-Cas9-generated SHP1 knockout cells as negative controls provides definitive evidence that observed signals are specific to SHP1 . Domain-swapping experiments, where SH2 domains of SHP1 are replaced with corresponding domains from SHP2 (or vice versa), offer powerful tools to validate the molecular basis of recruitment specificity, as demonstrated in studies of PD-1 and BTLA signaling . Competition assays with excess untagged SHP1 or specific phosphopeptides can displace specific interactions, reducing signal in a predictable manner if the observed recruitment is genuine. Phosphatase treatment of samples prior to analysis should eliminate recruitment dependent on phosphotyrosine motifs, providing evidence for phosphorylation-dependent specificity. Mutational analysis of receptor phosphotyrosine motifs offers another compelling approach—systematic mutation of tyrosine residues within ITIMs or ITSMs to phenylalanine should abolish SHP1 recruitment if the interaction occurs through the expected mechanism . Using multiple antibodies targeting different SHP1 epitopes helps rule out antibody artifacts, as consistent results across different antibodies strengthen confidence in observed patterns. Finally, correlation with functional outcomes provides biological validation—demonstrating that conditions or mutations enhancing SHP1 recruitment also strengthen inhibitory signaling outcomes, as shown with IL-2 secretion assays for PD-1 variants, establishes the functional relevance of observed recruitment patterns .